Advanced chronic kidney disease, cardiovascular events and the effect of diabetes: Data from the Atherosclerosis and Folic Acid Supplementation Trial

Internal Medicine Journal

Volumn 41, Issue 12, 2011, Pages 825-832

  Zoungas, S ^a,b   Lui, M ^a,b   Kerr, P G ^a   Teede, H J ^a,b   McNeil, J J ^a   McGrath, B P ^a   Polkinghorne, K R ^a  

^a MONASH UNIVERSITY   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

Author keywords

Cardiovascular disease; Chronic kidney disease; Diabetes mellitus; Mortality; Peripheral vascular disease; Risk factor

Indexed keywords

FOLIC ACID;

ADULT; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; FEMALE; FOLLOW UP; HAZARD RATIO; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SMOKING; STROKE; SYSTOLIC BLOOD PRESSURE; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; FOLIC ACID; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RISK FACTORS;

EID: 83355175570     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2010.02226.x     Document Type: Article

References (30)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-19.
2. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL etal. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32: 853-906.
3. McDonald SP, Excell L, Livingston B. Deaths. In: McDonald SP, ed. ANZDATA Registry Report 2006. Adelaide (SA): Australia and New Zealand Dialysis and Transplant Registry; 2006.
4. Excerpts from the United States Renal Data System. 1998 Annual Data Report. Am J Kidney Dis 1998; 32 (Suppl): S1-162.
5. Disney APS, ed. ANZDATA Report 1993. Adelaide (SA): Australia and New Zealand Dialysis and Transplant Registry; 1993.
6. Sarnak MJ, Levey AS. Epidemiology, diagnosis, and management of cardiac disease in chronic renal disease. J Thromb Thrombolysis 2000; 10: 169-80.
7. Tanaka Y, Joki N, Hase H. History of acute coronary events during the predialysis phase of chronic kidney disease is a strong risk factor for major adverse cardiac events in patients initiating haemodialysis. Nephrol Dial Transplant 2007; 22: 2917-23.
8. Hase H, Tsunoda T, Tanaka Y, Takahashi Y, Imamura Y, Ishikawa H etal. Risk factors for de novo acute cardiac events in patients initiating hemodialysis with no previous cardiac symptom. Kidney Int 2006; 70: 1142-8.
9. Manske CL, Wilson RF, Wang Y, Thomas W. Prevalence of, and risk factors for, angiographically determined coronary artery disease in type I-diabetic patients with nephropathy. Arch Intern Med 1992; 152: 2450-5.
10. Kalantar-Zadeh K, Kopple JD, Regidor DL, Jing J, Shinaberger CS, Aronovitz J etal. A1C and survival in maintenance hemodialysis patients. Diabetes Care 2007; 30: 1049-55.
11. Morioka TT, Emoto MM, Tabata TT, Shoji TT, Tahara HH, Kishimoto HH etal. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 2001; 24: 909-13.
12. Oomichi T, Emoto M, Tabata T, Morioka T, Tsujimoto Y, Tahara H etal. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care 2006; 29: 1496-500.
13. Tzamaloukas AH, Murata GH, Zager PG, Eisenberg B, Avasthi PS. The relationship between glycemic control and morbidity and mortality for diabetics on dialysis. ASAIO J 1993; 39: 880-5.
14. Williams ME, Lacson E Jr, Teng M, Ofsthun N, Lazarus JM. Hemodialyzed type I and type II diabetic patients in the US: characteristics, glycemic control, and survival. Kidney Int 2006; 70: 1503-9.
15. Wu M, Yu C, Yang C, Wu C, Haung J, Hong J etal. Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant 1997; 12: 2105-10.
16. Zoungas S, McGrath BP, Branley P, Kerr PG, Muske C, Wolfe R etal. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol 2006; 47: 1108-16.
17. Zoungas S, Branley P, Kerr PG, Ristevski S, Muske C, Demos L etal. Atherosclerosis and folic acid supplementation trial in chronic renal failure: baseline results. Nephrology 2004; 9: 130-41.
18. McDonald SP, Excell L, Livingston B. Deaths. In: McDonald SP, ed. ANZDATA Registry Report 2007. Adelaide (SA): Australia and New Zealand Dialysis and Transplant Registry; 2007.
19. Brown JH, Hunt LP, Vites NP, Short CD, Gokal R, Mallick NP. Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant 1994; 9: 1136-42.
20. United States Renal Data System. Mortality reference table H from USRDS 2007 Annual Data Report Atlas of Chronic Kidney Disease and End-stage renal disease in the United States National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2007.
21. McDonald SP, Chang S, Excell L. New Patients commencing treatment in 2005. In: McDonald SP, ed. ANZDATA Registry Report 2006. Adelaide (SA): Australia and New Zealand Dialysis and Transplant Registry; 2006.
22. Holland DC, Lam M. Predictors of hospitalization and death among pre-dialysis patients: a retrospective cohort study. Nephrol Dial Transplant 2000; 15: 650-8.
23. Lowrie EG, Lew NL, Huang WH. Race and diabetes as death risk predictors in hemodialysis patients. Kidney Int Suppl 1992; 38: S22-31.
24. Kerr PG, Guerin AP. Arterial calcification and stiffness in chronic kidney disease. Clin Exp Pharmacol Physiol 2007; 34: 683-7.
25. Rajagopalan S, Dellegrottaglie S, Furniss AL, Gillespie BW, Satayathum S, Lameire N etal. Peripheral arterial disease in patients with end-stage renal disease: observations from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Circulation 2006; 114: 1914-22.
26. Feringa HHH, Karagiannis SE, Chonchol M, Vidakovic R, Noordzij PG, Elhendy A etal. Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or angiotensin-converting enzyme inhibitors. J Am Soc Nephrol 2007; 18: 1872-79.
27. McMurray SD, Johnson G, Davis S, McDougall K. Diabetes education and care management significantly improve patient outcomes in the dialysis unit. Am J Kidney Dis 2002; 40: 566-75.
28. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M etal. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72.
29. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB etal. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.
30. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93.